NCT04763915Active, not recruiting
Improving Care After Inherited Cancer Testing
Improving Care After Inherited Cancer Testing (IMPACT) Study
Source: ClinicalTrials.gov · Last updated 19 Sept 2025
Brief summary (registry, in English)
The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and family communication (FC) of genetic test results for individuals with a documented pathogenic/likely pathogenic (P/LP) variant, and FC of family cancer history for individuals with a variant of uncertain significance (VUS) in an inherited cancer gene.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 720 (estimated)
- First submitted
- 15 Feb 2021
- Start date
- 5 Aug 2022
- Primary completion date
- Dec 2027
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- NCT number
- NCT04763915
What you commit to
- Study type: Interventional
- Planned participants: 720
- From 5 Aug 2022 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- English-speaking men and women aged 18 years or older
- Not adopted (i.e., have information about their biological relatives)
- Have access to internet and a computer, tablet, or smartphone
- Documented pathogenic/likely pathogenic variant in an inherited cancer gene that has CRM guidelines listed in the National Comprehensive Cancer Network (NCCN) Genetic/Familial Panel focused on Breast, Ovarian, and Pancreatic or Colorectal cancers
- Must meet at least one of the following criteria:
- Intervention A (GeneSHARE) criteria: Have at least one at-risk adult, living relative who either:
- has not been told about the genetic test result by the participant
- has not had their own genetic testing
- Intervention B (LivingLabReport) criteria: Are non-adherent (i.e., either undertreatment or overtreatment) to at least one of the current NCCN CRM guidelines or if currently adherent, require ongoing cancer screening
- VUS Pilot Study Eligibility: All VUS pilot study participants will be autonomous adults who are capable of participating in the study. Eligibility criteria include:
- English-speaking men and women aged 18 years or older
- Not adopted (i.e., have information about their biological relatives)
- Have access to internet and a computer, tablet, or smartphone
- Documented VUS in an inherited cancer gene
Criteria the registry did not label
- Randomized Controlled Trial Eligibility: All trial participants will be autonomous adults who are capable of participating in the study
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vanderbilt-Ingram Cancer Center Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.